Molecular Partners AG (XSWX:MOLN) Change In Receivables : CHF-1.42 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Change In Receivables?

Molecular Partners AG's change in receivables for the quarter that ended in Mar. 2024 was CHF-1.19 Mil. It means Molecular Partners AG's Accounts Receivable increased by CHF1.19 Mil from Dec. 2023 to Mar. 2024 .

Molecular Partners AG's change in receivables for the fiscal year that ended in Dec. 2023 was CHF-0.93 Mil. It means Molecular Partners AG's Accounts Receivable increased by CHF0.93 Mil from Dec. 2022 to Dec. 2023 .

Molecular Partners AG's Accounts Receivable for the quarter that ended in Mar. 2024 was CHF3.18 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Molecular Partners AG's Days Sales Outstanding for the three months ended in Mar. 2024 was 105.95.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Molecular Partners AG's liquidation value for the three months ended in Mar. 2024 was CHF159.46 Mil.

Molecular Partners AG Change In Receivables Historical Data

The historical data trend for Molecular Partners AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Change In Receivables Chart

Molecular Partners AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

49.57

-0.55

-23.37

25.26

-0.93

Molecular Partners AG Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.71	0.24	-0.26	-0.20	-1.19

Molecular Partners AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.42 Mil.

Molecular Partners AG (XSWX:MOLN) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Molecular Partners AG's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.179	/	2.738	*	91
=	105.95

2. In Ben Graham's calculation of liquidation value, Molecular Partners AG's accounts receivable are only considered to be worth 75% of book value:

Molecular Partners AG's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	174.133	-	17.06	+	0.75 * 3.179	+	0.5 * 0
=	159.46

Molecular Partners AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (XSWX:MOLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MOLN:USA MLLCF:USA MOLNz:UK 6ML0:Germany

Address

Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website

https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.